Instylla Announces FDA Clearance of Tembo™ Embolic System
BEDFORD, Mass., – Jan 28, 2025 – Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, has announced the FDA 510(k) clearance of the Tembo™ Embolic System. The Tembo Embolic System is a bioresorbable1 embolization agent comprised of irregularly shaped, dry gelatin particles of a size range from 85-255µm1…